No Data
No Data
Express News | Johnson & Johnson 13F Shows New Stake In Lyell Immunopharma
Lyell Immunopharma Price Target Lowered to 60c From $1 at BofA
BofA Securities Downgrades Lyell Immunopharma(LYEL.US) to Sell Rating, Cuts Target Price to $0.6
Lyell Immunopharma Accelerates Development of IMPT-314 for Large B-Cell Lymphoma, Discontinues LYL119 Program to Focus Resources
Lyell to Highlight Vision for Its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Bank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)